Ovarian hyperstimulation syndrome in a spontaneous pregnancy with a complete hydatidiform mole.

M. Strafford,N. Moreno-Ruiz,P. Stubblefield

DOI: https://doi.org/10.1016/j.fertnstert.2009.03.011

IF: 6.7

2009-07-01

Fertility and Sterility

Abstract:

What problem does this paper attempt to address?

Prioritization of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using Protein-Wide Mendelian Randomization Analysis

Jiawei Geng,Lu-Xi Chen,Chao-Sen Yang,Xixian Ruan,Shixian Hu,Jie Chen,Zhi-Ying Wu

DOI: https://doi.org/10.1101/2023.11.22.23298887

2023-01-01

Abstract:Background and Objectives Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease with an increasing global burden. Available treatments for ALS present marginal efficacy. To identify novel candidate therapeutic targets for ALS, we conducted a proteome-wide Mendelian randomization (MR) study. Methods We leveraged data from the largest summary statistics for ALS to date (27,205 patients with ALS and 110,881 controls). Genetic instruments of more than 4,000 proteins defined by cis -protein quantitative loci (pQTL) genetic instruments on plasma and cerebrospinal fluid (CSF) were obtained from Fenland (discovery, n=10,709), deCODE (replication, n=35,559), and a recently published dataset (replication, n=971). To investigate the causal ALS-associated proteins, proteome-wide Mendelian randomization based on summary-data-based MR (SMR and multi-SNP-based SMR) were performed. Then, two-sample MR analyses using five additional methods were conducted as sensitivity analyses. To further address the linkage disequilibrium bias, heterogeneity in dependent instruments test and colocalization analyses were performed. Steiger filtering and bi-directional MR analyses were conducted to address the potential reverse causality. Four drug target datasets were searched to extract druggability profiles for candidate target proteins. In addition, we carried out a case-control study involving up to 21 patients with ALS and 21 matched controls to assess the protein levels difference in CSF for evidence triangulation. Results Genetically predicted levels of six circulating proteins were associated with incident ALS in primary SMR analysis. After removing proteins with any linkage disequilibrium bias , SHBG , SIGLEC7, and SIGLEC9 presented consistent associations with ALS risk, supported by medium-to-high colocalization across both plasma pQTL datasets. In CSF, higher level of SHBG was also causally associated with the risk of ALS. There was no reverse causality detected. The case-control study using CSF proteomics conducted in our center observed consistent alteration in the levels of SHBG and SIGLEC7 with MR prediction, further suggesting their functionally relevant to ALS as potential druggable targets. Discussion Combined with the findings from MR and our observational study, we prioritize SHBG , SIGLEC7, and SIGLEC9 as drug candidate proteins for ALS, and further studies are needed to verify our findings and elucidate the underlying mechanism. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by the grant (81671245) to Zhi-Ying Wu from the National Natural Science Foundation of China and the Fundamental Research Funds for the Central Universities (2019XZZX001-01-04). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of the Second Affiliated Hospital gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data used in Mendelian randomization study are available from referenced datasets listed in eTable 1 . Data from the proteomics study are available upon reasonable request. * ALS : Amyotrophic lateral sclerosis ATF6B : activating transcription factor 6 Beta CSF : cerebrospinal fluid CI : confidence interval CNS : central nervous system FDR : False discovery rate HEIDI : heterogeneity in dependent instruments HDGFRP3 : Hepatoma-derived growth factor-related protein IVW : inverse variance weighted GWAS : genome-wide association study LD : Linkage disequilibrium MR : Mendelian randomization NME4 : Nucleoside Diphosphate Kinase 4 pQTL : protein quantitative loci SHBG : sex hormone binding globulin SIGLEC7 : sialic acid binding lg like lectin 7 SIGLEC9 : sialic acid binding lg like lectin 9 SMR : summary data-based Mendelian randomization SOD1 : superoxide dismutase 1 SD : standard deviation TMT : Tandem Mass Tag TDP-43 : TAR DNA-binding protein 43 TPP1 : Tripeptidyl Peptidase 1
Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Yahui Zhu,Mao Li,Hongfen Wang,Fei Yang,RongRong Du,Xinyuan Pang,Jiongming Bai,Xusheng Huang

DOI: https://doi.org/10.1007/s12035-023-03817-7

Abstract:Currently, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have no effective treatments. Drug repurposing offers a rapid method to meet therapeutic need for ALS and FTD. To identify therapeutic targets associated with ALS and FTD, Mendelian randomization (MR) analysis and colocalization were performed. Genetic instruments were based on transcriptomic and proteomic data for 422 actionable proteins targeted by approved drugs or clinical drug candidates. The publicly available ALS GWAS summary data (including a total of 20,806 ALS cases and 59,804 controls) and FTD GWAS summary data (including a total of 2154 patients with FTD and 4308 controls) were used. Using cis-expression quantitative trait loci and cis-protein quantitative trait loci genetic instruments, we identified several drug targets for repurposing (ALS: MARK3, false-discovery rate (FDR) = 0.043; LTBR, FDR = 0.068) (FTD: HLA-DRB1, FDR = 0.083; ADH5, FDR = 0.056). Our MR study analyzed the actionable druggable proteins and provided potential therapeutic targets for ALS and FTD. Future studies should further elucidate the underlying mechanism of corresponding drug targets in the pathogenesis of ALS and FTD.
Harnessing transcriptomic signals for amyotrophic lateral sclerosis to identify novel drugs and enhance risk prediction

Oliver Pain,Ashley Jones,Ahmad Al Khleifat,Devika Agarwal,Dzmitry Hramyka,Hajer Karoui,Jędrzej Kubica,David J Llewellyn,Janice M Ranson,Zhi Yao,Alfredo Iacoangeli,Ammar Al-Chalabi

DOI: https://doi.org/10.1016/j.heliyon.2024.e35342

IF: 3.776

2024-07-29

Heliyon

Abstract:Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. This study integrates common genetic association results from the latest ALS genome-wide association study (GWAS) summary statistics with functional genomic annotations with the aim of providing mechanistic insights into ALS risk loci, inferring drug repurposing opportunities, and enhancing prediction of ALS risk and clinical characteristics. Methods: Genes associated with ALS were identified using GWAS summary statistic methodology including SuSiE SNP-based fine-mapping, and transcriptome- and proteome-wide association study (TWAS/PWAS) analyses. Using several approaches, gene associations were integrated with the DrugTargetor drug-gene interaction database to identify drugs that could be repurposed for the treatment of ALS. Furthermore, ALS gene associations from TWAS were combined with observed blood expression in two external ALS case-control datasets to calculate polytranscriptomic scores and evaluate their utility for prediction of ALS risk and clinical characteristics, including site of onset, age at onset, and survival. Results: SNP-based fine-mapping, TWAS and PWAS identified 118 genes associated with ALS, with TWAS and PWAS providing novel mechanistic insights. Drug repurposing analyses identified six drugs significantly enriched for interactions with ALS associated genes, though directionality could not be determined. Additionally, drug class enrichment analysis showed gene signatures linked to calcium channel blockers may reduce ALS risk, whereas antiepileptic drugs may increase ALS risk. Across the two observed expression target samples, ALS polytranscriptomic scores significantly predicted ALS risk (R 2 = 5.1 %; p-value = 3.2 × 10-27) and clinical characteristics. Conclusions: Functionally-informed analyses of ALS GWAS summary statistics identified novel mechanistic insights into ALS aetiology, highlighted several therapeutic research avenues, and enabled statistically significant prediction of ALS risk.
Network medicine informed multi-omics integration identifies drug targets and repurposable medicines for Amyotrophic Lateral Sclerosis

Mucen Yu,Jielin Xu,Ranjan Dutta,Bruce Trapp,Andrew A. Pieper,Feixiong Cheng

DOI: https://doi.org/10.1101/2024.03.27.586949

2024-03-30

Abstract:Amyotrophic Lateral Sclerosis (ALS) is a devastating, immensely complex neurodegenerative disease by lack of effective treatments. To date, the challenge to establishing effective treatment for ALS remains formidable, partly due to inadequate translation of existing human genetic findings into actionable ALS-specific pathobiology for subsequent therapeutic development. This study evaluates the feasibility of network medicine methodology via integrating human brain-specific multi-omics data to prioritize drug targets and repurposable treatments for ALS. Using human brain-specific genome-wide quantitative trait loci (x-QTLs) under a network-based deep learning framework, we identified 105 putative ALS-associated genes enriched in various known ALS pathobiological pathways, including regulation of T cell activation, monocyte differentiation, and lymphocyte proliferation. Specifically, we leveraged non-coding ALS loci effects from genome-wide associated studies (GWAS) on brain-specific expression quantitative trait loci (QTL) (eQTL), protein QTLs (pQTL), splicing QTL (sQTL), methylation QTL (meQTL), and histone acetylation QTL (haQTL). Applying network proximity analysis of predicted ALS-associated gene-coding targets and existing drug-target networks under the human protein-protein interactome (PPI) model, we identified a set of potential repurposable drugs (including Diazoxide, Gefitinib, Paliperidone, and Dimethyltryptamine) for ALS. Subsequent validation established preclinical and clinical evidence for top-prioritized repurposable drugs. In summary, we presented a network-based multi-omics framework to identify potential drug targets and repurposable treatments for ALS and other neurodegenerative disease if broadly applied.

Systems Biology
Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization

Chen, Yong-Ping

DOI: https://doi.org/10.1007/s12035-024-04007-9

IF: 5.682

2024-02-08

Molecular Neurobiology

Abstract:Observational studies have faced challenges in identifying replicable causes for amyotrophic lateral sclerosis (ALS). To address this, we employed an unbiased and data-driven approach to discover and explore potential causal exposures using two-sample Mendelian randomization (MR) analyses. In the phenotype discovery stage, we assessed 3948 environmental exposures from the UK Biobank and utilized ALS summary statistics (Europeans, 20,806 cases, 59,804 controls) as the outcome within a phenome-wide MR pipeline. Through a range of sensitivity analyses, two medication traits were identified to be protective for ALS. In the target exploration stage, we further conducted drug target MR analyses using the latest and trans-ethnic summary data on lipid-related traits and ALS (Europeans, 27,205 cases, 110,881 controls; East Asians, 1234 cases, 2850 controls). Our aim was to explore potential causal drug targets through six lipid-modifying effects. These comprehensive analyses revealed significant findings. Specifically, "cholesterol-lowering medication" and "atorvastatin" survived predefined criteria in the phenotype discovery stage and exhibited a protective effect on ALS. Further in the target exploration stage, we demonstrated that the therapeutic effect of APOB through LDL-lowering was associated with reduced ALS liability in Europeans (OR = 0.835, P = 5.61E − 5). Additionally, the therapeutic effect of APOA1 and LDLR through TC-lowering was associated with reduced ALS liability in East Asians ( APOA1 , OR = 0.859, P = 5.38E − 4; LDLR , OR = 0.910, P = 2.73E − 5). Overall, we propose potential protective effects of cholesterol-lowering drugs or statins on ALS risk from thousands of exposures. Our research also suggests APOB , APOA1 , and LDLR as novel therapeutic targets for ALS and supports their potential protective mechanisms may be mediated by LDL-lowering or TC-lowering effects.

neurosciences
A Mendelian randomization study identifies proteins involved in neurodegenerative diseases

Lazaros Belbasis,Sam Morris,Cornelia van Duijn,Derrick Bennett,Robin Walters

DOI: https://doi.org/10.1101/2024.02.24.24303314

2024-02-27

Abstract:Proteins are involved in multiple biological functions. High-throughput technologies have allowed the measurement of thousands of proteins in population biobanks. In this study, we aimed to identify proteins related to Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) using large-scale genetic and proteomic data. We performed a two-sample Mendelian randomization (MR) study by selecting instrumental variables for the abundance of over 2,700 proteins measured by either Olink or SomaScan platforms in plasma from UK Biobank and the deCODE Health Study. We also used the latest publicly-available GWAS for the diseases of interest. The potentially causal effect of proteins on neurodegenerative diseases was estimated based on the Wald ratio. We tested 10,244 protein–disease associations, identifying 122 associations which were statistically significant (5% false discovery rate). Out of 57 associations (58%) tested using an instrumental variable from both Olink and SomaScan platforms, 33 (58%) were statistically significant in both platforms. Evidence of co-localisation between plasma protein abundance and disease risk (posterior probability >0.80) was identified for 46 protein-disease pairs. Twenty-three out of 46 protein–disease associations correspond to genetic loci not previously reported by genome-wide association studies. The newly-associated proteins for AD are involved in complement ( , ), microglia ( , ) and lysosomal functions ( ). A protein newly-associated with PD ( ) is involved in the interleukin-6 pathway, two proteins for ALS ( , ) are involved in lysosomal and astrocyte function, respectively, and proteins associated with MS are involved in blood–brain barrier function ( , ), the oligodendrocyte function ( ), the structure of the node of Ranvier and function of dorsal root ganglion ( , , ), and the response to viral infections including Epstein-Barr virus ( , ). Our study demonstrates how harnessing large-scale genomic and proteomic data can yield novel insights into the role of plasma proteome in the pathogenesis of neurodegenerative diseases.

Neurology
Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and amyotrophic lateral sclerosis

Chenxu Xiao,Xiaochu Gu,Yu Feng,Jing Shen

DOI: https://doi.org/10.3389/fnagi.2024.1367106

IF: 4.8

2024-03-28

Frontiers in Aging Neuroscience

Abstract:Introduction: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with poorly understood pathophysiology. Recent studies have highlighted systemic inflammation, especially the role of circulating inflammatory proteins, in ALS. Methods: This study investigates the potential causal link between these proteins and ALS. We employed a two-sample Mendelian Randomization(MR) approach, analyzing data from large-scale genome-wide association studies to explore the relationship between 91 circulating inflammatory proteins and ALS. This included various MR methods like MR Egger, weighted median, and inverse-variance weighted, complemented by sensitivity analyses for robust results. Results: Significant associations were observed between levels of inflammatory proteins, including Adenosine Deaminase, Interleukin-17C, Oncostatin-M, Leukemia Inhibitory Factor Receptor, and Osteoprotegerin, and ALS risk. Consistencies were noted across different P -value thresholds. Bidirectional MR suggested that ALS risk might influence levels of certain inflammatory proteins. Discussion: Our findings, via MR analysis, indicate a potential causal relationship between circulating inflammatory proteins and ALS. This sheds new light on ALS pathophysiology and suggests possible therapeutic targets. Further research is required to confirm these results and understand the specific roles of these proteins in ALS.

neurosciences,geriatrics & gerontology,gerontology
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis

Jianfeng Lin,Jiawei Zhou,Yan Xu

DOI: https://doi.org/10.1093/brain/awad070

IF: 14.5

2023-03-05

Brain

Abstract:Multiple sclerosis (MS) is a complex autoimmune disease, and several therapies for MS have been developed and widely used. However, existing medications for MS were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for MS prevention are still needed. We performed Mendelian randomization (MR) to explore potential drug targets for MS using summary statistics from the International Multiple Sclerosis Genetics Consortium (NCase = 47,429, NControl = 68,374) and further replicated in UK Biobank (NCase = 1,356, NControl = 395,209) and FinnGen cohorts (NCase = 1,326, NControl = 359,815). Genetic instruments for 734 plasma and 154 cerebrospinal fluid (CSF) proteins were obtained from recently published genome-wide association studies (GWAS). The reverse causality detection using bidirectional MR analysis and Steiger filtering, Bayesian colocalization, and phenotype scanning that searched previously-reported genetic variant-trait associations were implemented to consolidate the MR findings further. In addition, the protein-protein interaction (PPI) network was performed to reveal potential associations among proteins and/ or present MS medications. At Bonferroni significance (P < 5.63×10−5), MR analysis revealed six protein-MS pairs. In plasma, per SD increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratio (OR) for the proteins above were 0.83 (95% confidence interval [CI], 0.79-0.89), 0.59 (95% CI, 0.48-0.71), and 0.88 (95% CI, 0.83-0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42-7.41) increased the risk of MS, while SLAMF7 (OR, 0.42; 95% CI, 0.29-0.60) and CD5L (OR, 0.30; 95%CI, 0.18-0.52) decreased the risk. None of the six above proteins had reverse causality. Bayesian colocalization suggested that FCRL3 (coloc.abf-posterior probability of hypothesis 4 [PPH4] = 0.889), TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930), and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with MS. FCRL3, TYMP, and SLAMF7 interacted with target proteins of current MS medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically-determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1, and SLAMF7 had causal effects on MS risk. These findings suggested those five proteins might be promising drug targets for MS and warrant further clinical investigation, especially FCRL3 and SLAMF7.

neurosciences,clinical neurology
Evidence based on Mendelian randomization and colocalization analysis strengthens causal relationships between structural changes in specific brain regions and risk of amyotrophic lateral sclerosis

Jiaying Shi,Zhaokun Wang,Ming Yi,Shengyu Xie,Xinyue Zhang,Dachang Tao,Yunqiang Liu,Yuan Yang

DOI: https://doi.org/10.3389/fnins.2024.1333782

IF: 4.3

2024-03-06

Frontiers in Neuroscience

Abstract:Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the degeneration of motor neurons in the brain and spinal cord with a poor prognosis. Previous studies have observed cognitive decline and changes in brain morphometry in ALS patients. However, it remains unclear whether the brain structural alterations contribute to the risk of ALS. In this study, we conducted a bidirectional two-sample Mendelian randomization (MR) and colocalization analysis to investigate this causal relationship. Methods: Summary data of genome-wide association study were obtained for ALS and the brain structures, including surface area (SA), thickness and volume of subcortical structures. Inverse-variance weighted (IVW) method was used as the main estimate approach. Sensitivity analysis was conducted detect heterogeneity and pleiotropy. Colocalization analysis was performed to calculate the posterior probability of causal variation and identify the common genes. Results: In the forward MR analysis, we found positive associations between the SA in four cortical regions (lingual, parahippocampal, pericalcarine, and middle temporal) and the risk of ALS. Additionally, decreased thickness in nine cortical regions (caudal anterior cingulate, frontal pole, fusiform, inferior temporal, lateral occipital, lateral orbitofrontal, pars orbitalis, pars triangularis, and pericalcarine) was significantly associated with a higher risk of ALS. In the reverse MR analysis, genetically predicted ALS was associated with reduced thickness in the bankssts and increased thickness in the caudal middle frontal, inferior parietal, medial orbitofrontal, and superior temporal regions. Colocalization analysis revealed the presence of shared causal variants between the two traits. Conclusion: Our results suggest that altered brain morphometry in individuals with high ALS risk may be genetically mediated. The causal associations of widespread multifocal extra-motor atrophy in frontal and temporal lobes with ALS risk support the notion of a continuum between ALS and frontotemporal dementia. These findings enhance our understanding of the cortical structural patterns in ALS and shed light on potentially viable therapeutic targets.

neurosciences
Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis

Yanni Ma,Tingting Jia,Fengqin Qin,Yongji He,Feng Han,Chengcheng Zhang

DOI: https://doi.org/10.1007/s12035-023-03587-2

Abstract:Due to the limitations of the present risk genes in understanding the etiology of amyotrophic lateral sclerosis (ALS), it is necessary to find additional causative genes utilizing novel approaches. In this study, we conducted a two-stage proteome-wide association study (PWAS) using ALS genome-wide association study (GWAS) data (N = 152,268) and two distinct human brain protein quantitative trait loci (pQTL) datasets (ROSMAP N = 376 and Banner N = 152) to identify ALS risk genes and prioritized candidate genes with Mendelian randomization (MR) and Bayesian colocalization analysis. Next, we verified the aberrant expression of risk genes in multiple tissues, including lower motor neurons, skeletal muscle, and whole blood. Six ALS risk genes (SCFD1, SARM1, TMEM175, BCS1L, WIPI2, and DHRS11) were found during the PWAS discovery phase, and SARM1 and BCS1L were confirmed during the validation phase. The following MR (p = 2.10 × 10-7) and Bayesian colocalization analysis (ROSMAP PP4 = 0.999, Banner PP4 = 0.999) confirmed the causal association between SARM1 and ALS. Further differential expression analysis revealed that SARM1 was markedly downregulated in lower motor neurons (p = 7.64 × 10-3), skeletal muscle (p = 9.34 × 10-3), and whole blood (p = 1.94 × 10-3). Our findings identified some promising protein candidates for future investigation as therapeutic targets. The dysregulation of SARM1 in multiple tissues provides a new way to explain ALS pathology.
Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

Frank W. Pun,Bonnie Hei Man Liu,Xi Long,Hoi Wing Leung,Geoffrey Ho Duen Leung,Quinlan T. Mewborne,Junli Gao,Anastasia Shneyderman,Ivan V. Ozerov,Ju Wang,Feng Ren,Alexander Aliper,Evelyne Bischof,Evgeny Izumchenko,Xiaoming Guan,Ke Zhang,Bai Lu,Jeffrey D. Rothstein,Merit E. Cudkowicz,Alex Zhavoronkov

DOI: https://doi.org/10.3389/fnagi.2022.914017

IF: 4.8

2022-06-28

Frontiers in Aging Neuroscience

Abstract:Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease with ill-defined pathogenesis, calling for urgent developments of new therapeutic regimens. Herein, we applied PandaOmics, an AI-driven target discovery platform, to analyze the expression profiles of central nervous system (CNS) samples (237 cases; 91 controls) from public datasets, and direct iPSC-derived motor neurons (diMNs) (135 cases; 31 controls) from Answer ALS. Seventeen high-confidence and eleven novel therapeutic targets were identified and will be released onto ALS.AI (http://als.ai/). Among the proposed targets screened in the c9ALS Drosophila model, we verified 8 unreported genes ( KCNB2 , KCNS3 , ADRA2B , NR3C1 , P2RY14 , PPP3CB , PTPRC , and RARA ) whose suppression strongly rescues eye neurodegeneration. Dysregulated pathways identified from CNS and diMN data characterize different stages of disease development. Altogether, our study provides new insights into ALS pathophysiology and demonstrates how AI speeds up the target discovery process, and opens up new opportunities for therapeutic interventions.

neurosciences,geriatrics & gerontology,gerontology
Genome-Wide and Transcriptome-Wide Association Studies on Northern New England and Ohio Amyotrophic Lateral Sclerosis Cohorts

Siting Li,Jiang Gui,Michael N Passarelli,Angeline S Andrew,Kathleen M Sullivan,Kevin A Cornell,Bryan J Traynor,Ali Stark,Ruth Chia,Rebecca M Kuenzler,Erik P Pioro,Walter G Bradley,Elijah W Stommel

DOI: https://doi.org/10.1212/NXG.0000000000200188

2024-09-06

Abstract:Background and objectives: Amyotrophic lateral sclerosis (ALS) is an age-associated, fatal neurodegenerative disorder causing progressive paralysis and respiratory failure. The genetic architecture of ALS is still largely unknown. Methods: We performed a genome-wide association study (GWAS) and transcriptome-wide association study (TWAS) to understand genetic risk factors for ALS using a population-based case-control study of 435 ALS cases and 279 controls from Northern New England and Ohio. Single nucleotide polymorphism (SNP) genotyping was conducted using the Illumina NeuroChip array. Odds ratios were estimated using covariate-adjusted logistic regression. We also performed a genome-wide SNP-smoking interaction screening. TWAS analyses used PrediXcan to estimate associations between predicted gene expression levels across 15 tissues (13 brain tissues, skeletal muscle, and whole blood) and ALS risk. Results: GWAS analyses identified the p.A382T missense variant (rs367543041, p = 3.95E-6) in the TARDBP gene, which has previously been reported in association with increased ALS risk and was found to share a close affinity with the Sardinian haplotype. Both GWAS and TWAS analyses suggested that ZNF235 is associated with decreased ALS risk. Discussion: Our results support the need for future evaluation to clarify the role of these potential genetic risk factors for ALS and to understand genetic susceptibility to environmental risk factors.
Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

Yi-Jun Ge,Ya-Nan Ou,Yue-Ting Deng,Bang-Sheng Wu,Liu Yang,Ya-Ru Zhang,Shi-Dong Chen,Yu-Yuan Huang,Qiang Dong,Lan Tan,Jin-Tai Yu,International FTD-Genomics Consortium,Raffaele Ferrari,Dena G Hernandez,Michael A Nalls,Jonathan D Rohrer,Adaikalavan Ramasamy,John B J Kwok,Carol Dobson-Stone,William S Brooks,Peter R Schofield,Glenda M Halliday,John R Hodges,Olivier Piguet,Lauren Bartley,Elizabeth Thompson,Eric Haan,Isabel Hernández,Agustín Ruiz,Mercè Boada,Barbara Borroni,Alessandro Padovani,Carlos Cruchaga,Nigel J Cairns,Luisa Benussi,Giuliano Binetti,Roberta Ghidoni,Gianluigi Forloni,Daniela Galimberti,Chiara Fenoglio,Maria Serpente,Elio Scarpini,Jordi Clarimón,Alberto Lleó,Rafael Blesa,Maria Landqvist Waldö,Karin Nilsson,Christer Nilsson,Ian R A Mackenzie,Ging-Yuek R Hsiung,David M A Mann,Jordan Grafman,Christopher M Morris,Johannes Attems,Timothy D Griffiths,Ian G McKeith,Alan J Thomas,P Pietrini,Edward D Huey,Eric M Wassermann,Atik Baborie,Evelyn Jaros,Michael C Tierney,Pau Pastor,Cristina Razquin,Sara Ortega-Cubero,Elena Alonso,Robert Perneczky,Janine Diehl-Schmid,Panagiotis Alexopoulos,Alexander Kurz,Innocenzo Rainero,Elisa Rubino,Lorenzo Pinessi,Ekaterina Rogaeva,Peter St George-Hyslop,Giacomina Rossi,Fabrizio Tagliavini,Giorgio Giaccone,James B Rowe,Johannes C M Schlachetzki,James Uphill,John Collinge,Simon Mead,Adrian Danek,Vivianna M Van Deerlin,Murray Grossman,John Q Trojanowski,Julie van der Zee,William Deschamps,Tim Van Langenhove,Marc Cruts,Christine Van Broeckhoven,Stefano F Cappa,Isabelle Le Ber,Didier Hannequin,Véronique Golfier,Martine Vercelletto,Alexis Brice,Benedetta Nacmias,Sandro Sorbi,Silvia Bagnoli,Irene Piaceri,Jørgen E Nielsen,Lena E Hjermind,Matthias Riemenschneider,Manuel Mayhaus,Bernd Ibach,Gilles Gasparoni,Sabrina Pichler,Wei Gu,Martin N Rossor,Nick C Fox,Jason D Warren,Maria Grazia Spillantini,Huw R Morris,Patrizia Rizzu,Peter Heutink,Julie S Snowden,Sara Rollinson,Anna Richardson,Alexander Gerhard,Amalia C Bruni,Raffaele Maletta,Francesca Frangipane,Chiara Cupidi,Livia Bernardi,Maria Anfossi,Maura Gallo,Maria Elena Conidi,Nicoletta Smirne,Rosa Rademakers,Matt Baker,Dennis W Dickson,Neill R Graff-Radford,Ronald C Petersen,David Knopman,Keith A Josephs,Bradley F Boeve,Joseph E Parisi,William W Seeley,Bruce L Miller,Anna M Karydas,Howard Rosen,John C van Swieten,Elise G P Dopper,Harro Seelaar,Yolande A L Pijnenburg,Philip Scheltens,Giancarlo Logroscino,Rosa Capozzo,Valeria Novelli,Annibale A Puca,Massimo Franceschi,Alfredo Postiglione,Graziella Milan,Paolo Sorrentino,Mark Kristiansen,Huei-Hsin Chiang,Caroline Graff,Florence Pasquier,Adeline Rollin,Vincent Deramecourt,Florence Lebert,Dimitrios Kapogiannis,Luigi Ferrucci,Stuart Pickering-Brown,Andrew B Singleton,John Hardy,Parastoo Momeni

DOI: https://doi.org/10.1016/j.biopsych.2022.11.002

2023-05-01

Abstract:Background: Neurodegenerative diseases are among the most prevalent and devastating neurological disorders, with few effective prevention and treatment strategies. We aimed to integrate genetic and proteomic data to prioritize drug targets for neurodegenerative diseases. Methods: We screened human proteomes through Mendelian randomization to identify causal mediators of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, and Lewy body dementia. For instruments, we used brain and blood protein quantitative trait loci identified from one genome-wide association study with 376 participants and another with 3301 participants, respectively. Causal associations were subsequently validated by sensitivity analyses and colocalization. The safety and druggability of identified targets were also evaluated. Results: Our analyses showed targeting BIN1, GRN, and RET levels in blood as well as ACE, ICA1L, MAP1S, SLC20A2, and TOM1L2 levels in brain might reduce Alzheimer's disease risk, while ICA1L, SLC20A2, and TOM1L2 were not recommended as prioritized drugs due to the identified potential side effects. Brain CD38, DGKQ, GPNMB, and SEC23IP were candidate targets for Parkinson's disease. Among them, GPNMB was the most promising target for Parkinson's disease with their causal relationship evidenced by studies on both brain and blood tissues. Interventions targeting FCRL3, LMAN2, and MAPK3 in blood and DHRS11, FAM120B, SHMT1, and TSFM in brain might affect multiple sclerosis risk. The risk of amyotrophic lateral sclerosis might be reduced by medications targeting DHRS11, PSMB3, SARM1, and SCFD1 in brain. Conclusions: Our study prioritized 22 proteins as targets for neurodegenerative diseases and provided preliminary evidence for drug development. Further studies are warranted to validate these targets.
Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study

Kailin Xia,Veronika Klose,Josef Högel,Tao Huang,Linjing Zhang,Johannes Dorst,Dongsheng Fan,Albert C Ludolph

DOI: https://doi.org/10.1111/ene.15810

Abstract:Objective: Previous observational studies revealed a potential but partially controversial relation between lipid metabolism and the risk of amyotrophic lateral sclerosis (ALS), potentially prone to bias. Therefore, we aimed to study whether lipid metabolism involves genetically determined risk factors for ALS through Mendelian randomization (MR) analysis. Methods: Using genome-wide association study summary-level data for total cholesterol (TC) (n = 188,578), high-density lipoprotein cholesterol (HDL-C) (n = 403,943), low-density lipoprotein cholesterol (LDL-C) (n = 440,546), apolipoprotein A1 (ApoA1) (n = 391,193), apolipoprotein B (ApoB) (n = 439,214), and ALS (12,577 cases and 23,475 controls), we implemented a bidirectional MR study to evaluate a genetic relation between lipids and ALS risk. We performed a mediation analysis to assess whether LDL-C is a potential mediator on the pathway from traits of LDL-C-related polyunsaturated fatty acids (PUFAs) to ALS risk. Results: We identified genetically predicted increased lipid levels to be associated with the risk of ALS, whereby elevated LDL-C had the most potent effect (OR 1.028, 95% CI 1.008-1.049, p = 0.006). The effect of increased levels of apolipoproteins on ALS was similar to their corresponding lipoproteins. ALS did not cause any changes in lipid levels. We found no relation between LDL-C-modifying lifestyles and ALS. The mediation analysis revealed that LDL-C could act as an active mediator for linoleic acid, with the mediation effect estimated to be 0.009. Conclusions: We provided high-level genetic evidence verifying the positive link between preclinically elevated lipid and ALS risk that had been described in previous genetic and observational studies. We also demonstrated the mediating role of LDL-C in the pathway from PUFAs to ALS.
Key Molecules and Pathways Underlying Sporadic Amyotrophic Lateral Sclerosis: Integrated Analysis on Gene Expression Profiles of Motor Neurons

Jianing Lin,Pian Huang,Weineng Chen,Chenghui Ye,Huanxing Su,Xiaoli Yao

DOI: https://doi.org/10.3389/fgene.2020.578143

IF: 3.7

2020-11-09

Frontiers in Genetics

Abstract:Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive loss of motor neurons. The complex mechanisms underlying ALS are yet to be elucidated, while the lack of disease biomarkers and therapeutic options are associated with the poor prognosis of ALS patients. In this study, we performed bioinformatics analysis to clarify potential mechanisms in sporadic ALS (sALS). We compared three gene expression profiles (GSE18920, GSE56500, and GSE68605) of motor neurons obtained from sALS patients and healthy controls to discover differentially expressed genes (DEGs), and then performed integrated bioinformatics analyses to identify key molecules and pathways underlying sALS. We found that these DEGs were mainly enriched in the structure and functions of extracellular matrix (ECM), while functional enrichment in blood vessel morphogenesis was less correlated with motor neurons. The clustered subnetworks of the constructed protein-protein interaction network for DEGs and the group of selected hub genes were more significantly involved in the organization of collagen-containing ECM. The transcriptional factors database proposed RelA and NF-κB1 from NF-κB family as the key regulators of these hub genes. These results mainly demonstrated the alternations in ECM-related gene expression in motor neurons and suggested the role of NF-κB regulatory pathway in the pathogenesis of sALS.

genetics & heredity
Genetic analyses identify brain imaging-derived phenotypes associated with the risk of amyotrophic lateral sclerosis

Yinan Wang,Ouxi Shen,Qingyun Xu,Lulu Sun,Yiming Jia,Yi Liu,Yu He,Xinyue Chang,Daoxia Guo,Mengyao Shi,Guo-Chong Chen,Jin Zheng,Zhengbao Zhu

DOI: https://doi.org/10.1093/cercor/bhad496

IF: 4.861

2023-12-20

Cerebral Cortex

Abstract:Brain imaging-derived phenotypes have been suggested to be associated with amyotrophic lateral sclerosis in observational studies, but whether these associations are causal remains unclear. We aimed to assess the potential bidirectional causal associations between imaging-derived phenotypes and amyotrophic lateral sclerosis using bidirectional 2-sample Mendelian randomization analyses. Summary statistics for 469 imaging-derived phenotypes (33,224 individuals) and amyotrophic lateral sclerosis (20,806 cases and 59,804 controls) were obtained from 2 large-scale genome-wide association studies of European ancestry. We used the inverse-variance weighted Mendelian randomization method in the main analysis to assess the bidirectional associations between imaging-derived phenotypes and amyotrophic lateral sclerosis, followed by several sensitivity analyses for robustness validation. In the forward Mendelian randomization analyses, we found that genetically determined high orientation dispersion index in the right cerebral peduncle was associated with the increased risk of amyotrophic lateral sclerosis (odds ratio = 1.30, 95% confidence interval = 1.16–1.45, P = 2.26 × 10−6). In addition, the reverse Mendelian randomization analysis indicated that amyotrophic lateral sclerosis had no effect on 469 imaging-derived phenotypes. Mendelian randomization-Egger regression analysis showed no directional pleiotropy for the association between high orientation dispersion index in the right cerebral peduncle and amyotrophic lateral sclerosis, and sensitivity analyses with different Mendelian randomization models further confirmed these findings. The present systematic bidirectional Mendelian randomization analysis showed that high orientation dispersion index in the right cerebral peduncle might be the potential causal mediator of amyotrophic lateral sclerosis, which may provide predictive guidance for the prevention of amyotrophic lateral sclerosis. Further studies are warranted to replicate our findings and clarify the underlying mechanisms.

neurosciences
Novel Insight Into the Role of Immune Dysregulation in Amyotrophic Lateral Sclerosis Based on Bioinformatic Analysis

Yongzhi Xie,Ximei Luo,Haiqing He,Min Tang

DOI: https://doi.org/10.3389/fnins.2021.657465

IF: 4.3

2021-04-30

Frontiers in Neuroscience

Abstract:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The causative pathogenic mechanisms in ALS remain unclear, limiting the development of treatment strategies. Neuroinflammation and immune dysregulation were involved in the disease onset and progression of several neurodegenerative disorders, including ALS. In this study, we carried out a bioinformatic analysis using publicly available datasets from Gene Expression Omnibus (GEO) to investigate the role of immune cells and genes alterations in ALS. Single-sample gene set enrichment analysis revealed that the infiltration of multiple types of immune cells, including macrophages, type-1/17 T helper cells, and activated CD4 + /CD8 + T cells, was higher in ALS patients than in controls. Weighted gene correlation network analysis identified immune genes associated with ALS. The Gene Ontology analysis revealed that receptor and cytokine activities were the most highly enriched terms. Pathway analysis showed that these genes were enriched not only in immune-related pathways, such as cytokine-cytokine receptor interaction, but also in PI3K-AKT and MAPK signaling pathways. Nineteen immune-related genes ( C3AR1 , CCR1 , CCR5 , CD86 , CYBB , FCGR2B , FCGR3A , HCK , ITGB2 , PTPRC , TLR1 , TLR2 , TLR7 , TLR8 , TYROBP , VCAM1 , CD14 , CTSS , and FCER1G ) were identified as hub genes based on least absolute shrinkage and selection operator analysis. This gene signature could differentiate ALS patients from non-neurological controls ( p < 0.001) and predict disease occurrence (AUC = 0.829 in training set; AUC = 0.862 in test set). In conclusion, our study provides potential biomarkers of ALS for disease diagnosis and therapeutic monitoring.

neurosciences
Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients

Qiuying Chen,Davinder Sandhu,Csaba Konrad,Dipa Roychoudhury,Benjamin I. Schwartz,Roger R. Cheng,Kirsten Bredvik,Hibiki Kawamata,Elizabeth L. Calder,Lorenz Studer,Steven. M. Fischer,Giovanni Manfredi,Steven. S. Gross

DOI: https://doi.org/10.1101/416396

2018-09-13

Abstract:Abstract Sporadic amyotrophic lateral sclerosis (sALS) is a progressive motor neuron disease resulting in paralysis and death. Genes responsible for familial ALS have been identified, however the molecular basis for sALS is unknown. To discover metabotypic biomarkers that inform on disease etiology, untargeted metabolite profiling was performed on 77 patient-derived dermal fibroblast lines and 45 age/sex-matched controls. Surprisingly, 25% of sALS lines showed upregulated methionine-derived homocysteine, channeled to cysteine and glutathione (GSH). Stable isotope tracing of [U- 13 C]-glucose showed activation of the trans-sulfuration pathway, associated with accelerated glucose flux into the TCA cycle, glutamate, GSH, alanine, aspartate, acylcarnitines and nucleotide phosphates. A four-molecule support vector machine model distinguished the sALS subtype from controls with 97.5% accuracy. Plasma metabolite profiling identified increased taurine as a hallmark metabolite for this sALS subset, suggesting systemic perturbation of cysteine metabolism. Furthermore, integrated multiomics (mRNAs/microRNAs/metabolites) identified the super-trans-sulfuration pathway as a top hit for the sALS subtype. We conclude that sALS can be stratified into distinct metabotypes, providing for future development of personalized therapies that offer new hope to sufferers.
Suicide Clusters : A Discussion ! " ! Acknowledgements !

Discussion,Clusters,Appendices,Resources,References

Abstract:
Genetically Predicted Circulating Concentrations of Micronutrients and Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study

Changqing Mu,Yating Zhao,Chen Han,Dandan Tian,Na Guo,Chenguang Zhang,Ruixia Zhu,Xiaoqian Zhang,Jian Zhang,Xu Liu

DOI: https://doi.org/10.3389/fgene.2021.811699

IF: 3.7

2022-01-17

Frontiers in Genetics

Abstract:Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative disease with increasing incidence and high mortality, resulting in a considerable socio-economic burden. Till now, plenty of studies have explored the potential relationship between circulating levels of various micronutrients and ALS risk. However, the observations remain equivocal and controversial. Thus, we conducted a two-sample Mendelian randomization (MR) study to investigate the causality between circulating concentrations of 9 micronutrients, including retinol, folate acid, vitamin B12, B6 and C, calcium, copper, zinc as well as magnesium, and ALS susceptibility. In our analysis, several single nucleotide polymorphisms were collected as instrumental variables from large-scale genome-wide association studies of these 9 micronutrients. Then, inverse variance weighted (IVW) approach as well as alternative MR-Egger regression, weighted median and MR-pleiotropy residual sum and outlier (MR-PRESSO) analyses were performed to evaluate causal estimates. The results from IVW analysis showed that there was no causal relationship of 9 micronutrients with ALS risk. Meanwhile, the three complementary approaches obtained similar results. Thus, our findings indicated that supplementation of these 9 micronutrients may not play a clinically effective role in preventing the occurrence of ALS.

genetics & heredity

Ovarian hyperstimulation syndrome in a spontaneous pregnancy with a complete hydatidiform mole.

Prioritization of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using Protein-Wide Mendelian Randomization Analysis

Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Harnessing transcriptomic signals for amyotrophic lateral sclerosis to identify novel drugs and enhance risk prediction

Network medicine informed multi-omics integration identifies drug targets and repurposable medicines for Amyotrophic Lateral Sclerosis

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization

A Mendelian randomization study identifies proteins involved in neurodegenerative diseases

Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and amyotrophic lateral sclerosis

Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis

Evidence based on Mendelian randomization and colocalization analysis strengthens causal relationships between structural changes in specific brain regions and risk of amyotrophic lateral sclerosis

Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

Genome-Wide and Transcriptome-Wide Association Studies on Northern New England and Ohio Amyotrophic Lateral Sclerosis Cohorts

Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study

Key Molecules and Pathways Underlying Sporadic Amyotrophic Lateral Sclerosis: Integrated Analysis on Gene Expression Profiles of Motor Neurons

Genetic analyses identify brain imaging-derived phenotypes associated with the risk of amyotrophic lateral sclerosis

Novel Insight Into the Role of Immune Dysregulation in Amyotrophic Lateral Sclerosis Based on Bioinformatic Analysis

Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients

Suicide Clusters : A Discussion ! " ! Acknowledgements !

Genetically Predicted Circulating Concentrations of Micronutrients and Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study